Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
Research grant supports study on effects of various radiation types used in radionuclide therapy in cancer research (STRIPE) by NCI.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 5, 2025 (New) | March 5, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $500,000 direct costs per year, for up to 5 years (R01 mechanism)
Summary: Supports preclinical research on the biological effects of different radiation types used in radionuclide-based cancer therapeutics, excluding clinical trials.
Key Information: Clinical trials are not allowed; applications must include experimental testing of radionuclide-based agents.
Description
This funding opportunity, issued by the National Cancer Institute (NCI) at NIH, solicits R01 research projects that use advanced cancer biology methods and model systems to systematically study the effects of various types of radiation used in radionuclide-based therapeutics (such as radiopharmaceutical therapy) on normal tissue, tumor cells, and the tumor microenvironment. The goal is to address gaps in understanding the biological mechanisms and optimize the use of radionuclide therapies in cancer treatment.
The program encourages collaborative, multidisciplinary projects—especially those with multiple principal investigators representing expertise in both radiotherapeutics and cancer biology. The research supported is intended to inform future clinical trial design but does not fund clinical trials directly.
